Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04992520 · ClinicalTrials.gov registry record · Phase 1
Controlled Human Infection Model Challenge/Rechallenge
A Phase 1 study, sponsored by PATH.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04992520 is a Phase 1 study that has completed, run by PATH. The registered enrollment target is 46 participants.
The verdict
NCT04992520, a Phase 1 study, has completed, sponsored by PATH.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of this study is to better understand Shigella immunity. The study will compare the shigellosis rate in participants previously challenged with a different Shigella serotype to the attack rate in participants not previously exposed to Shigella (naive participants).
Interventions
- BIOLOGICAL Shigella sonnei 53G
- BIOLOGICAL Shigella flexneri 2a 2457T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2023-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04992520
The ClinicalTrials.gov registry entry for NCT04992520 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PATH, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Shigella sonnei 53G is the first listed.
NCT04992520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04992520 about?
NCT04992520 is a clinical study titled "Controlled Human Infection Model Challenge/Rechallenge". The goal of this study is to better understand Shigella immunity. The study will compare the shigellosis rate in participants previously challenged with a different Shigella serotype to the attack rate in participants not previously exposed to Shigella (naive participants).
What is the current status of trial NCT04992520?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2022-04-26. Estimated completion is 2023-08-29.
What interventions are being tested in trial NCT04992520?
The interventions under investigation include: Shigella sonnei 53G (BIOLOGICAL), Shigella flexneri 2a 2457T (BIOLOGICAL).
Who is sponsoring clinical trial NCT04992520?
This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.